6Abbo KM, Dooris M, Glazier S, et al. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol, 1995,75:778-782.
7Kloner RA, Ganote CE, Jennings RB. The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J Clin Invest, 1974,54 : 1496-1508.
8Schofer J, Montz R, Mathey DG. Scintigraphic evidence of the “no reflow” phenomenon in human beings after coronary thrombolysis. J Am Coll Cardiol, 1985,5:593-598.
9Bates ER, Krell MJ, Dean EN, et al. Demonstration of the “no-reflow” phenomenon by digital coronary arteriography. Am J Cardiol, 1986,57 : 177-178.
10Marzilli M, Orsini E, Marraccini P, et al. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation, 2000,101:2154-2159.
3Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the "no-reflow" phenomenon: A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction[J]. Circulation, 1996,93:223-228.
4Ni-coli G, Burzotta F, Galiuto L, et al. Myocardial No-Reflow in Humans[J]. J Am Coll Cardiol,2009;54:281-292.
5Wang Y, Schmeichel AM, Iida H, et al. Enhanced inflammatory response via activation of NF-K B in acute experimental diabetic neuropathy sbjected to ischemia-reperfusion injury [J]. Neurological Sciences,2006, 247:47-52.
6Brosh D, Assali AR, Mager A, et al. Effect of No-reflow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction on Six-Month Mortality[J].The American Journal of Cardiology,2007: 99:442-445.
7Romano M, Buffoli F ,Lettieri C ,et al. No reflow in patients undergoing primary angioplasty for acute myocardial infarction at high risk: incidence and predictive factors [J]. Minerva Cardioangiol, 2005, 53 (1):7-14.
8Kojima S, Sakamoto T, Ishihara M. The white blood cell count is an independent predictor of no-reflow and mortality following acute myocardial infarction in the coronary interventional era [J]. Ann Med, 2004, 36:153- 160.
9Laga M, Cottyn A, Herreweghe FV, et al. Methylglyoxal suppresses TNF-α-induced NF-K B activation by inhibiting NF-K B DNA-bind- ing[J]. Biochemical Pharmacology,2007,74:579-589.
10Sgueglia GA, Niccoli G, Spaziani C,et al, Baseline von Willebrand factor plasma levels and no-reflow phenomenon after primary pereutaneous coronary intervention for ST segment elevation myocardial infarction[J]. Int J Cardiol,2009, doi: 10.1016/j.ij card.2009.07.046.
